Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating income | -$39.3M | -$26.3M | -$17.6M | -$15.7M | -$10.2M | -$14.3M | -$21.6M | -$21.4M | -$26.3M | -$24.1M |
| Net income | -$27.8M | -$15.5M | -$13.4M | -$15.4M | -$10.1M | -$14.3M | -$19.7M | -$18.3M | -$25.7M | -$23.7M |
| EPS (diluted) | -$0.29 | -$6.23 | -$4.06 | -$0.98 | -$0.66 | -$1.90 | -$1.31 | -$28.48 | -$19.03 | -$2.08 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$27.9M | -$20.2M | -$17.3M | -$13.9M | -$12.2M | -$12.9M | -$19.1M | -$19.0M | -$16.9M | -$16.7M |
| Capital expenditures | $569K | $212K | $7.00K | $0.00 | $9.00K | $14.0K | $116K | $202K | $1.00K | $35.0K |
| Free cash flow | -$28.5M | -$20.4M | -$17.3M | -$13.9M | -$12.2M | -$12.9M | -$19.2M | -$19.2M | -$16.9M | -$16.7M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $19.1M | $17.1M | $28.9M | $15.0M | $6.23M | $67.3M | $41.8M | $23.2M | $11.6M | $13.1M |
| Total assets | $22.5M | $18.8M | $30.1M | $17.2M | $8.41M | $70.4M | $71.9M | $55.2M | $35.4M | $38.2M |
| Total liabilities | $20.2M | $10.2M | $3.69M | $5.75M | $3.15M | $4.96M | $17.3M | $15.5M | $16.3M | $22.9M |
| Long-term debt | — | — | — | — | — | — | $221K | $162K | $92.0K | $1.67M |
| Shareholders' equity | $2.26M | -$3.41M | $14.2M | -$1.06M | -$7.54M | $65.4M | $51.8M | $37.0M | $19.1M | $15.4M |
| Retained earnings | -$172M | -$194M | -$219M | -$236M | -$248M | -$271M | -$291M | -$309M | -$335M | -$359M |
| Shares (wtd avg diluted) | 117M | 3.67M | 15.5M | 16.8M | 19.0M | 12.2M | 15.3M | 644K | 1.35M | 12.1M |
Every figure is extracted from Theriva Biologics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.